[Detection of 3q27 chromosomal abnormality in diffuse large B cell lymphoma using FISH on cell microarray]

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous non-Hodgkin lymphoma.
• Understanding the genetic and molecular underpinnings of DLBCL is crucial for improving patient outcomes.
• The role of chromosome 3q27 rearrangements and bcl-6 gene amplification in DLBCL pathogenesis requires further elucidation.

Purpose of the Study:

• To investigate the association between 3q27 chromosome rearrangement and bcl-6 gene amplification in DLBCL.
• To correlate these genetic alterations with molecular subtypes (GCB vs. non-GCB).
• To analyze the impact of these factors on therapeutic efficacies and clinical stages.

Main Methods:

• Utilized cell microarray and fluorescence in situ hybridization (FISH) to detect 3q27 rearrangement and bcl-6 gene amplification in 60 DLBCL cases.
• Employed immunohistochemistry (IHC) and tissue microarray for molecular classification (GCB/non-GCB) based on CD20, CD10, bcl-6, and MUM1 expression.
• Collected and analyzed clinical data on therapeutic responses and disease stages.

Main Results:

• 3q27 rearrangement was found in 15 cases, with significantly lower bcl-6 protein expression compared to cases without rearrangement (P=0.017).
• bcl-6 gene amplification occurred in 22 cases, predominantly in the non-GCB subtype (77.3%, P=0.003), and was associated with worse therapeutic results (P=0.016).
• No significant correlation was observed between bcl-6 gene/protein status and clinical stages; BCL-6 protein expression did not correlate with therapeutic efficacy.

Conclusions:

• bcl-6 gene fragmentation is associated with reduced BCL-6 protein expression.
• bcl-6 gene amplification in DLBCL is linked to the non-GCB subtype, worse therapeutic outcomes, and advanced clinical stages.
• Other genes near chromosome 3q27 may play a role in DLBCL prognosis, warranting further investigation.